JP2021515572A5 - - Google Patents

Info

Publication number
JP2021515572A5
JP2021515572A5 JP2020548674A JP2020548674A JP2021515572A5 JP 2021515572 A5 JP2021515572 A5 JP 2021515572A5 JP 2020548674 A JP2020548674 A JP 2020548674A JP 2020548674 A JP2020548674 A JP 2020548674A JP 2021515572 A5 JP2021515572 A5 JP 2021515572A5
Authority
JP
Japan
Prior art keywords
aavrh74
modified
recombinant
cells
item
Prior art date
Application number
JP2020548674A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019178412A5 (https=
JP2021515572A (ja
JP7304878B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022353 external-priority patent/WO2019178412A1/en
Publication of JP2021515572A publication Critical patent/JP2021515572A/ja
Publication of JPWO2019178412A5 publication Critical patent/JPWO2019178412A5/ja
Publication of JP2021515572A5 publication Critical patent/JP2021515572A5/ja
Priority to JP2023104920A priority Critical patent/JP2023115149A/ja
Application granted granted Critical
Publication of JP7304878B2 publication Critical patent/JP7304878B2/ja
Priority to JP2024117744A priority patent/JP2024144521A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020548674A 2018-03-16 2019-03-14 キャプシド改変による組織特異的遺伝子送達の増加 Active JP7304878B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023104920A JP2023115149A (ja) 2018-03-16 2023-06-27 キャプシド改変による組織特異的遺伝子送達の増加
JP2024117744A JP2024144521A (ja) 2018-03-16 2024-07-23 キャプシド改変による組織特異的遺伝子送達の増加

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644317P 2018-03-16 2018-03-16
US62/644,317 2018-03-16
PCT/US2019/022353 WO2019178412A1 (en) 2018-03-16 2019-03-14 Increasing tissue specific gene delivery by capsid modification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023104920A Division JP2023115149A (ja) 2018-03-16 2023-06-27 キャプシド改変による組織特異的遺伝子送達の増加

Publications (4)

Publication Number Publication Date
JP2021515572A JP2021515572A (ja) 2021-06-24
JPWO2019178412A5 JPWO2019178412A5 (https=) 2022-03-03
JP2021515572A5 true JP2021515572A5 (https=) 2022-03-03
JP7304878B2 JP7304878B2 (ja) 2023-07-07

Family

ID=67906893

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020548674A Active JP7304878B2 (ja) 2018-03-16 2019-03-14 キャプシド改変による組織特異的遺伝子送達の増加
JP2023104920A Pending JP2023115149A (ja) 2018-03-16 2023-06-27 キャプシド改変による組織特異的遺伝子送達の増加
JP2024117744A Pending JP2024144521A (ja) 2018-03-16 2024-07-23 キャプシド改変による組織特異的遺伝子送達の増加

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023104920A Pending JP2023115149A (ja) 2018-03-16 2023-06-27 キャプシド改変による組織特異的遺伝子送達の増加
JP2024117744A Pending JP2024144521A (ja) 2018-03-16 2024-07-23 キャプシド改変による組織特異的遺伝子送達の増加

Country Status (11)

Country Link
US (2) US12385062B2 (https=)
EP (1) EP3765624A4 (https=)
JP (3) JP7304878B2 (https=)
KR (3) KR20250111395A (https=)
CN (2) CN118373887A (https=)
AU (2) AU2019234918C1 (https=)
BR (1) BR112020018354A2 (https=)
CA (3) CA3293599A1 (https=)
IL (2) IL277270B2 (https=)
SG (1) SG11202008687XA (https=)
WO (1) WO2019178412A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018003665A2 (en) 2015-09-28 2018-09-25 The University Of North Carolina At Chapel Hill methods and compositions for antibody evasion viral vectors
CN118373887A (zh) 2018-03-16 2024-07-23 国家儿童医院研究所 通过衣壳修饰增加组织特异性的基因递送
CA3094465A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
CN112543766A (zh) 2018-04-03 2021-03-23 斯特里迪比奥公司 抗体逃避性病毒载体
US20210363191A1 (en) 2018-04-03 2021-11-25 Stridebio, Inc. Antibody-evading virus vectors
BR112021018776A2 (pt) 2019-03-21 2021-11-30 Stridebio Inc Vetores de vírus adenoassociado recombinante
KR20220083714A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
EP4200408A1 (en) 2020-08-19 2023-06-28 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of rett syndrome
US20240299586A1 (en) * 2021-05-06 2024-09-12 The Regents Of The University Of California Novel aav serotypes derived from a library screen
CA3247417A1 (en) 2022-04-06 2023-10-12 Genzyme Corporation TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY
JP2026511976A (ja) * 2023-04-05 2026-04-14 ジェンザイム・コーポレーション Ｄｍ－１筋強直性ジストロフィーの標的遺伝子療法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
CN1856576B (zh) * 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
AU2013249202B2 (en) 2012-04-18 2018-08-09 The Children's Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using AAV capsid variants
KR20240090694A (ko) 2013-07-22 2024-06-21 더 칠드런스 호스피탈 오브 필라델피아 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
AU2015335923B2 (en) * 2014-10-21 2021-04-29 University Of Massachusetts Recombinant AAV variants and uses thereof
BR112018003665A2 (en) * 2015-09-28 2018-09-25 The University Of North Carolina At Chapel Hill methods and compositions for antibody evasion viral vectors
AU2017250791B2 (en) * 2016-04-15 2022-11-24 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy
FI3445773T3 (fi) * 2016-05-13 2023-03-30 4D Molecular Therapeutics Inc Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä
CN118373887A (zh) 2018-03-16 2024-07-23 国家儿童医院研究所 通过衣壳修饰增加组织特异性的基因递送
WO2020047472A1 (en) 2018-08-30 2020-03-05 Research Institute At Nationwide Children's Hospital Gene therapy for the treatment of galactosemia

Similar Documents

Publication Publication Date Title
JP2021515572A5 (https=)
Chang et al. Characterization of the DNA binding properties of polyomavirus capsid protein
CN109608550B (zh) 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN113663073B (zh) 一种靶向s蛋白棕榈酰化的多肽在制备广谱抗冠状病毒药物中的应用
US6884431B1 (en) Method for treating proliferative diseases with p27 and fusions thereof
JP2021520203A5 (https=)
Park et al. Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina
US6685934B1 (en) Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)
CN114729009A (zh) 用于眼部基因递送的aav载体变体
IL277270B1 (en) Increasing tissue-specific gene delivery through capsid modification
JP2019537437A5 (https=)
WO2021233346A1 (zh) 一种被靶向修饰且装载有药物的外泌体及其制备方法和应用
JPWO2019178412A5 (https=)
JP2004528266A (ja) 薬物送達用組成物
CN116925192B (zh) 一种融合型腺相关病毒及其应用
CA2514781A1 (en) Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor
US11510999B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
WO2024066780A1 (zh) 一种融合型新型腺相关病毒及其应用
JP2001524934A (ja) 遺伝子治療ウイルスベクターの投与に対して哺乳類罹患動物を寛容化する方法
JP2022501046A5 (https=)
JP2000500986A (ja) レトロウイルスベクターおよび遺伝子治療におけるその用途
JPWO2003103721A1 (ja) 脳血管障害遺伝子治療剤
CN109836490A (zh) 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用
HS Shilpashree BDS et al. Gene therapy in dentistry: a review
US11459364B2 (en) Calbindin and BH3 domain chimeric proteins and methods for use